DDInter122 DDInter785
Artesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin]. Artesunate was granted FDA approval on 26 May 2020.
Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.[A235008, A235013, A235018]
Fostamatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Fostamatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ripretinib
Fostamatinib {u} may lead to a major life threatening interaction when taken with {v} Clarithromycin
Fostamatinib {u} may lead to a major life threatening interaction when taken with {v} Berotralstat
Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Fostamatinib may lead to a major life threatening interaction when taken with Clarithromycin
Fostamatinib may lead to a major life threatening interaction when taken with Berotralstat